Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice.

1. Petersmann, A., Müller-Wieland, D., Müller, U. A., Landgraf, R., Nauck,

M., Freckmann, G., Heinemann, L., and Schleicher, E. (2019) Definition,

classification and diagnosis of diabetes mellitus. Exp. Clin. Endocrinol.

Diabetes 127, S1–S7

2. Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L.,

Groop, P. H., Handelsman, Y., Insel, R. A., Mathieu, C., McElvaine, A. T.,

Palmer, J. P., Pugliese, A., Schatz, D. A., Sosenko, J. M., et al. (2017)

Differentiation of diabetes by pathophysiology, natural history, and

prognosis. Diabetes 66, 241–255

J. Biol. Chem. (2021) 296 100761

15

DPPIII for diabetic heart and kidney

3. Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U.,

Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., and Makaroff, L. E.

(2017) IDF diabetes atlas: Global estimates for the prevalence of diabetes

for 2015 and 2040. Diabetes Res. Clin. Pract. 128, 40–50

4. Bullard, K. M., Cowie, C. C., Lessem, S. E., Saydah, S. H., Menke, A.,

Geiss, L. S., Orchard, T. J., Rolka, D. B., and Imperatore, G. (2018)

Prevalence of diagnosed diabetes in adults by diabetes type - United

States, 2016. MMWR Morb. Mortal. Wkly. Rep. 67, 359–361

5. Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E., and Gregg, E. W.

(2019) Global trends in diabetes complications: A review of current evidence. Diabetologia 62, 3–16

6. Rawshani, A., Franzén, S., Eliasson, B., Svensson, A. M., Miftaraj, M.,

McGuire, D. K., Sattar, N., Rosengren, A., and Gudbjörnsdottir, S. (2017)

Mortality and cardiovascular disease in type 1 and type 2 diabetes. N.

Engl. J. Med. 376, 1407–1418

7. Constantino, M. I., Molyneaux, L., Limacher-Gisler, F., Al-Saeed, A., Luo, C.,

Wu, T., Twigg, S. M., Yue, D. K., and Wong, J. (2013) Long-term complications and mortality in young-onset diabetes: Type 2 diabetes is more

hazardous and lethal than type 1 diabetes. Diabetes Care 36, 3863–3869

8. Jia, G., Whaley-Connell, A., and Sowers, J. R. (2018) Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease.

Diabetologia 61, 21–28

9. Gluhovschi, C., Gluhovschi, G., Petrica, L., Timar, R., Velciov, S., Ionita,

I., Kaycsa, A., and Timar, B. (2016) Urinary biomarkers in the assessment

of early diabetic nephropathy. J. Diabetes Res. 2016, 4626125

10. Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N.,

Deaton, C., Escaned, J., Hammes, H. P., Huikuri, H., Marre, M., Marx, N.,

Mellbin, L., Ostergren, J., Patrono, C., et al. (2013) ESC guidelines on

diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The task force on diabetes, pre-diabetes, and

cardiovascular diseases of the European Society of Cardiology (ESC) and

developed in collaboration with the European Association for the Study

of Diabetes (EASD). Eur. Heart J. 34, 3035–3087

11. Boudina, S., and Abel, E. D. (2010) Diabetic cardiomyopathy, causes and

effects. Rev. Endocr. Metab. Disord. 11, 31–39

12. Muddu, M., Mutebi, E., and Mondo, C. (2016) Prevalence, types and

factors associated with echocardiographic abnormalities among newly

diagnosed diabetic patients at Mulago Hospital. Afr. Health Sci. 16, 183–

193

13. Yadava, S. K., Dolma, N., Lamichhane, G., Poudel, N., Barakoti, M., and

Karki, D. B. (2017) Prevalence of diastolic dysfunction in type 2 diabetes

mellitus. Kathmandu Univ. Med. J. (KUMJ) 15, 212–216

14. Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H.,

Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., Neumiller, J. J., Patel, U. D., Ratner, R. E., WhaleyConnell, A. T., and Molitch, M. E. (2014) Diabetic kidney disease: A

report from an ADA consensus conference. Diabetes Care 37, 2864–2883

15. Anders, H. J., Huber, T. B., Isermann, B., and Schiffer, M. (2018) CKD in

diabetes: Diabetic kidney disease versus nondiabetic kidney disease. Nat.

Rev. Nephrol. 14, 361–377

16. Lin, Y. C., Chang, Y. H., Yang, S. Y., Wu, K. D., and Chu, T. S. (2018)

Update of pathophysiology and management of diabetic kidney disease. J.

Formos. Med. Assoc. 117, 662–675

17. Garcia-Fernandez, N., Jacobs-Cachá, C., Mora-Gutiérrez, J. M., Vergara,

A., Orbe, J., and Soler, M. J. (2020) Matrix metalloproteinases in diabetic

kidney disease. J. Clin. Med. 9, 472

18. Parving, H. H., Lewis, J. B., Ravid, M., Remuzzi, G., Hunsicker, L. G., and

DEMAND Investigators (2006) Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global

perspective. Kidney Int. 69, 2057–2063

19. Pambianco, G., Costacou, T., Ellis, D., Becker, D. J., Klein, R., and Orchard, T. J. (2006) The 30-year natural history of type 1 diabetes complications: The Pittsburgh Epidemiology of Diabetes Complications Study

experience. Diabetes 55, 1463–1469

20. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes

(UKPDS 33). Lancet 352, 837–853

16 J. Biol. Chem. (2021) 296 100761

21. Writing, Team for the Diabetes Control and Complications Trial/

Epidemiology of Diabetes Interventions and Complications Research

Group (2003) Sustained effect of intensive treatment of type 1 diabetes

mellitus on development and progression of diabetic nephropathy: The

Epidemiology of Diabetes Interventions and Complications (EDIC) study.

JAMA 290, 2159–2167

22. Nathan, D. M., Cleary, P. A., Backlund, J. Y., Genuth, S. M., Lachin, J. M.,

Orchard, T. J., Raskin, P., Zinman, B., and Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes

treatment and cardiovascular disease in patients with type 1 diabetes. N.

Engl. J. Med. 353, 2643–2653

23. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven,

P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R.,

Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., et al. (2009)

Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139

24. Ford, E. S. (2011) Trends in the control of risk factors for cardiovascular

disease among adults with diagnosed diabetes: Findings from the National

Health and Nutrition Examination survey 1999-2008. J. Diabetes 3, 337–

347

25. Nathan, D. M., and DCCT/EDIC Research Group (2014) The diabetes

control and complications trial/epidemiology of diabetes interventions

and complications study at 30 years: Overview. Diabetes Care 37, 9–16

26. Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J., Fleisher, M., Robbins, R. J., and Tempst, P. (2006) Serum peptidome patterns that

distinguish metastatic thyroid carcinoma from cancer-free controls are

unbiased by gender and age. Mol. Cell. Proteomics 5, 1840–1852

27. Takakuwa, Y., Kurokawa, M. S., Ooka, S., Sato, T., Nagai, K., Arito, M.,

Suematsu, N., Okamoto, K., Nagafuchi, H., Yamada, H., Ozaki, S., and

Kato, T. (2011) AC13, a C-terminal fragment of apolipoprotein A-I, is a

candidate biomarker for microscopic polyangiitis. Arthritis Rheum. 63,

3613–3624

28. Prajapati, S. C., and Chauhan, S. S. (2011) Dipeptidyl peptidase III: A

multifaceted oligopeptide N-end cutter. FEBS J. 278, 3256–3276

29. Lee, C. M., and Snyder, S. H. (1982) Dipeptidyl-aminopeptidase III of rat

brain. Selective affinity for enkephalin and angiotensin. J. Biol. Chem. 257,

12043–12050

30. Pang, X., Shimizu, A., Kurita, S., Zankov, D. P., Takeuchi, K., YasudaYamahara, M., Kume, S., Ishida, T., and Ogita, H. (2016) Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension.

Hypertension 68, 630–641

31. Coleman, D. L., and Hummel, K. P. (1967) Studies with the mutation,

diabetes, in the mouse. Diabetologia 3, 238–248

32. Alex, L., Russo, I., Holoborodko, V., and Frangogiannis, N. G. (2018)

Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved

ejection fraction. Am. J. Physiol. Heart Circ. Physiol. 315, H934–H949

33. Abdurrachim, D., Nabben, M., Hoerr, V., Kuhlmann, M. T., Bovenkamp,

P., Ciapaite, J., Geraets, I. M. E., Coumans, W., Luiken, J. J. F. P., Glatz, J.

F. C., Schäfers, M., Nicolay, K., Faber, C., Hermann, S., and Prompers, J. J.

(2017) Diabetic db/db mice do not develop heart failure upon pressure

overload: A longitudinal in vivo PET, MRI, and MRS study on cardiac

metabolic, structural, and functional adaptations. Cardiovasc. Res. 113,

1148–1160

34. Anzai, T. (2018) Inflammatory mechanisms of cardiovascular remodeling.

Circ. J. 82, 629–635

35. Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm,

K. A., Zoungas, S., Rossing, P., Groop, P. H., and Cooper, M. E. (2015)

Diabetic kidney disease. Nat. Rev. Dis. Primers 1, 15018

36. Ganu, V. S., Müller-Eberhard, H. J., and Hugli, T. E. (1989) Factor C3f is a

spasmogenic fragment released from C3b by factors I and H: The

heptadeca-peptide C3f was synthesized and characterized. Mol. Immunol.

26, 939–948

37. Braga, V. M. (2002) Cell-cell adhesion and signalling. Curr. Opin. Cell

Biol. 14, 546–556

38. Wojciak-Stothard, B., and Ridley, A. J. (2002) Rho GTPases and the

regulation of endothelial permeability. Vascul. Pharmacol. 39, 187–199

DPPIII for diabetic heart and kidney

39. Hall, A. (1998) Rho GTPases and the actin cytoskeleton. Science 279,

509–514

40. Lara-Astiaso, D., Izarra, A., Estrada, J. C., Albo, C., Moscoso, I., Samper,

E., Moncayo, J., Solano, A., Bernad, A., and Díez-Juan, A. (2012) Complement anaphylatoxins C3a and C5a induce a failing regenerative program in cardiac resident cells. Evidence of a role for cardiac resident stem

cells other than cardiomyocyte renewal. Springerplus 1, 63

41. Fukuoka, Y., Tachibana, T., and Yasui, A. (1994) Anaphylatoxin C3a induces rapid protein phosphorylation in Guinea pig platelets. Immunopharmacology 28, 95–104

42. Mehta, D., Rahman, A., and Malik, A. B. (2001) Protein kinase C-alpha

signals rho-guanine nucleotide dissociation inhibitor phosphorylation and

rho activation and regulates the endothelial cell barrier function. J. Biol.

Chem. 276, 22614–22620

43. Wilkinson, M. J., Zadourian, A., and Taub, P. R. (2019) Heart failure and

diabetes mellitus: Defining the problem and exploring the interrelationship. Am. J. Cardiol. 124, S3–S11

44. Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine,

K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., Ronco, C.,

Tang, W. H. W., McCullough, P. A., and American Heart Association

Council on the Kidney in Cardiovascular Disease and Council on Clinical

Cardiology (2019) Cardiorenal syndrome: Classification, pathophysiology,

diagnosis, and treatment strategies: A scientific statement from the

American Heart Association. Circulation 139, e840–e878

45. Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G.,

Erondu, N., Shaw, W., Law, G., Desai, M., Matthews, D. R., and CANVAS

Program Collaborative Group (2017) Canagliflozin and cardiovascular

and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657

46. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L.,

Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C.

P., Capuano, G., Chu, P. L., de Zeeuw, D., Greene, T., et al. (2019)

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N.

Engl. J. Med. 380, 2295–2306

47. Abramic, M., Simaga, S., Osmak, M., Cicin-Sain, L., Vukelic, B., Vlahovicek, K., and Dolovcak, L. (2004) Highly reactive cysteine residues are

part of the substrate binding site of mammalian dipeptidyl peptidases III.

Int. J. Biochem. Cell Biol. 36, 434–446

48. Hast, B. E., Goldfarb, D., Mulvaney, K. M., Hast, M. A., Siesser, P. F., Yan,

F., Hayes, D. N., and Major, M. B. (2013) Proteomic analysis of ubiquitin

ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

Cancer Res. 73, 2199–2210

49. Li, N., Venkatesan, M. I., Miguel, A., Kaplan, R., Gujuluva, C., Alam, J.,

and Nel, A. (2000) Induction of heme oxygenase-1 expression in macrophages by diesel exhaust particle chemicals and quinones via the

antioxidant-responsive element. J. Immunol. 165, 3393–3401

50. McMahon, M., Itoh, K., Yamamoto, M., and Hayes, J. D. (2003) Keap1dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven

gene expression. J. Biol. Chem. 278, 21592–21600

51. Gamrekelashvili, J., Kapanadze, T., Han, M., Wissing, J., Ma, C., Jaensch,

L., Manns, M. P., Armstrong, T., Jaffee, E., White, A. O., Citrin, D. E.,

Korangy, F., and Greten, T. F. (2013) Peptidases released by necrotic cells

control CD8+ T cell cross-priming. J. Clin. Invest. 123, 4755–4768

52. Dépret, F., Amzallag, J., Pollina, A., Fayolle-Pivot, L., Coutrot, M., Chaussard,

M., Santos, K., Hartmann, O., Jully, M., Fratani, A., Oueslati, H., Cupaciu, A.,

Benyamina, M., Guillemet, L., Deniau, B., et al. (2020) Circulating dipeptidyl

peptidase-3 at admission is associated with circulatory failure, acute kidney

injury and death in severely ill burn patients. Crit. Care 24, 168

53. Deniau, B., Rehfeld, L., Santos, K., Dienelt, A., Azibani, F., Sadoune, M.,

Kounde, P. R., Samuel, J. L., Tolpannen, H., Lassus, J., Harjola, V. P.,

Vodovar, N., Bergmann, A., Hartmann, O., Mebazaa, A., et al. (2020)

Circulating dipeptidyl peptidase 3 is a myocardial depressant factor:

Dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur. J. Heart Fail. 22, 290–299

54. Deniau, B., Blet, A., Santos, K., Vaittinada Ayar, P., Genest, M., Kästorf,

M., Sadoune, M., de Sousa Jorge, A., Samuel, J. L., Vodovar, N., Bergmann, A., Mebazaa, A., and Azibani, F. (2020) Inhibition of circulating

dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model

in rats: A proof of concept study. PLoS One 15, e0238039

55. Rossignol, P., Hernandez, A. F., Solomon, S. D., and Zannad, F. (2019)

Heart failure drug treatment. Lancet 393, 1034–1044

56. Sarafidis, P. A., and Ruilope, L. M. (2014) Aggressive blood pressure

reduction and renin-angiotensin system blockade in chronic kidney disease: Time for re-evaluation. Kidney Int. 85, 536–546

57. Yuan, S. Y., Breslin, J. W., Perrin, R., Gaudreault, N., Guo, M., Kargozaran, H., and Wu, M. H. (2007) Microvascular permeability in diabetes

and insulin resistance. Microcirculation 14, 363–373

58. Rask-Madsen, C., and King, G. L. (2013) Vascular complications of diabetes: Mechanisms of injury and protective factors. Cell Metab. 17, 20–33

59. Jamwal, S., and Sharma, S. (2018) Vascular endothelium dysfunction: A

conservative target in metabolic disorders. Inflamm. Res. 67, 391–405

60. Schraufstatter, I. U., Trieu, K., Sikora, L., Sriramarao, P., and DiScipio, R.

(2002) Complement c3a and c5a induce different signal transduction

cascades in endothelial cells. J. Immunol. 169, 2102–2110

61. Li, X. Q., Chang, D. Y., Chen, M., and Zhao, M. H. (2019) Deficiency of

C3a receptor attenuates the development of diabetic nephropathy. BMJ

Open Diabetes Res. Care 7, e000817

62. Morigi, M., Perico, L., Corna, D., Locatelli, M., Cassis, P., Carminati, C. E.,

Bolognini, S., Zoja, C., Remuzzi, G., Benigni, A., and Buelli, S. (2020) C3a

receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight 5, e131849

63. Müller-Eberhard, H. J. (1988) Molecular organization and function of the

complement system. Annu. Rev. Biochem. 57, 321–347

64. Cui, J., Wu, X., Song, Y., Chen, Y., and Wan, J. (2019) Complement C3

exacerbates renal interstitial fibrosis by facilitating the M1 macrophage

phenotype in a mouse model of unilateral ureteral obstruction. Am. J.

Physiol. Renal Physiol 317, F1171–F1182

65. Gombos, T., Förhécz, Z., Pozsonyi, Z., Széplaki, G., Kunde, J., Füst, G.,

Jánoskuti, L., Karádi, I., and Prohászka, Z. (2012) Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure.

Clin. Res. Cardiol. 101, 607–615

66. Zipfel, P. F., Wiech, T., Rudnick, R., Afonso, S., Person, F., and Skerka, C.

(2019) Complement inhibitors in clinical trials for glomerular diseases.

Front. Immunol. 10, 2166

67. Zankov, D. P., Shimizu, A., Tanaka-Okamoto, M., Miyoshi, J., and Ogita,

H. (2017) Protective effects of intercalated disk protein afadin on chronic

pressure overload-induced myocardial damage. Sci. Rep. 7, 39335

68. Wang, L., Liu, C., Chen, X., and Li, P. (2019) Alamandine attenuates longterm hypertension-induced cardiac fibrosis independent of blood pressure. Mol. Med. Rep. 19, 4553–4560

69. Miles, A. A., and Miles, E. M. (1952) Vascular reactions to histamine,

histamine-liberator and leukotaxine in the skin of Guinea-pigs. J. Physiol.

118, 228–257

70. Ahmat Amin, M. K. B., Shimizu, A., Zankov, D. P., Sato, A., Kurita, S.,

Ito, M., Maeda, T., Yoshida, T., Sakaue, T., Higashiyama, S., Kawauchi, A.,

and Ogita, H. (2018) Epithelial membrane protein 1 promotes tumor

metastasis by enhancing cell migration via copine-III and Rac1. Oncogene

37, 5416–5434

71. Majima, T., Takeuchi, K., Sano, K., Hirashima, M., Zankov, D. P., TanakaOkamoto, M., Ishizaki, H., Miyoshi, J., and Ogita, H. (2013) An adaptor

molecule afadin regulates lymphangiogenesis by modulating RhoA activity in the developing mouse embryo. PLoS One 8, e68134

72. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M.,

Pérez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., Yilmaz, S., et al.

(2019) The PRIDE database and related tools and resources in 2019:

Improving support for quantification data. Nucleic Acids Res. 47, D442–

D450

J. Biol. Chem. (2021) 296 100761

17

...